Prader-Willi Syndrome Treatment Market Size in the 7MM was more than ~USD 600 million in 2023 and It is expected to grow by 2034, estimates DelveInsight

DelveInsight's "Prader-Willi Syndrome Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Prader-Willi Syndrome, historical and forecasted epidemiology as well as the Prader-Willi Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. The Prader-Willi Syndrome market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Prader-Willi Syndrome pipeline products will significantly revolutionize the Prader-Willi Syndrome market dynamics.

To know in detail about the Prader-Willi Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here @ https://www.delveinsight.com/sample-request/prader-willi-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Some of the key facts of the Prader-Willi Syndrome Market Report
• In October 2025, Harmony Biosciences Management Inc. announced a study will consist of a Screening Period, an 11-week Double-Blind Treatment Phase (including a 3-week Titration Period and an 8-week Stable Dose Period), and an optional Open Label Extension (OLE) Phase. The OLE Phase will be multi-year in duration and will continue until the Sponsor elects to terminate the study.
• In October 2025, Aardvark Therapeutics Inc. conducted a clinical trial is to learn if ARD-101 works to treat hyperphagia-related behavior in patients with Prader-Willi syndrome (PWS). It will also teach us about the safety of ARD-101. Researchers will compare ARD-101 to a placebo (a look-alike substance that contains no drug) to see if ARD-101 works to treat hyperphagia in PWS subjects.
• In October 2025, Rhythm Pharmaceuticals Inc. initiated a Phase 2 study designed to assess the safety and efficacy of setmelanotide in patients with obesity due to Prader-Willi Syndrome (PWS) who are 6 to 65 years of age. Up to 20 patients are planned to be enrolled. Patients will take a daily subcutaneous dose of open-label setmelanotide for up to 52 weeks.
• The leading Prader-Willi Syndrome Companies such as Novo Nordisk, Pfizer, Sandoz, Harmony Biosciences, Soleno Therapeutics, Harmony Biosciences, ACADIA Pharmaceuticals, Aardvark Therapeutics, Gedeon Richter, Palobiofarma, ConSynance Therapeutics, and others
• Promising Prader-Willi Syndrome Therapies such as NORDITROPIN, GENOTROPIN, OMNITROPE, WAKIX (pitolisant), Diazoxide Choline Controlled-Release (DCCR), WAKIX (pitolisant), DCCR (diazoxide choline), Carbetocin (LV-101), ARD-101, RGH-706, PBF-999, CSTI-500, and others

Navigate the complexities of the Prader-Willi Syndrome Market: gain insights into drug trends, treatment scenarios, and epidemiological data through our insightful Prader-Willi Syndrome Market Forecast. Click here to get more insights @ https://www.delveinsight.com/sample-request/prader-willi-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Prader-Willi Syndrome Epidemiology Segmentation in the 7MM
• Total Prevalence of Prader-Willi Syndrome
• Prevalent Cases of Prader-Willi Syndrome by severity
• Gender-specific Prevalence of Prader-Willi Syndrome
• Diagnosed Cases of Episodic and Chronic Prader-Willi Syndrome

Download the report to understand which factors are driving Prader-Willi Syndrome epidemiology trends @ Prader-Willi Syndrome Prevalence- https://www.delveinsight.com/sample-request/prader-willi-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Prader-Willi Syndrome Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Prader-Willi Syndrome market or expected to get launched during the study period. The analysis covers Prader-Willi Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share. The report also covers the Prader-Willi Syndrome Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Prader-Willi Syndrome Therapies and Companies
• NORDITROPIN: Novo Nordisk
• GENOTROPIN: Pfizer
• OMNITROPE: Sandoz
• WAKIX (pitolisant): Harmony Biosciences
• Diazoxide Choline Controlled-Release (DCCR): Soleno Therapeutics
• WAKIX (pitolisant): Harmony Biosciences
• DCCR (diazoxide choline): Soleno Therapeutics
• Carbetocin (LV-101): ACADIA Pharmaceuticals
• ARD-101: Aardvark Therapeutics
• RGH-706: Gedeon Richter
• PBF-999: Palobiofarma
• CSTI-500: ConSynance Therapeutics

Discover more about therapies set to grab major Prader-Willi Syndrome market share @ Prader-Willi Syndrome Treatment Landscape- https://www.delveinsight.com/sample-request/prader-willi-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Prader-Willi Syndrome Market Report
• Study Period: 2020-2034
• Coverage: 7MM
• Prader-Willi Syndrome Companies: Novo Nordisk, Pfizer, Sandoz, Harmony Biosciences, Soleno Therapeutics, Harmony Biosciences, ACADIA Pharmaceuticals, Aardvark Therapeutics, Gedeon Richter, Palobiofarma, ConSynance Therapeutics, and others
• Prader-Willi Syndrome Therapies: NORDITROPIN, GENOTROPIN, OMNITROPE, WAKIX (pitolisant), Diazoxide Choline Controlled-Release (DCCR), WAKIX (pitolisant), DCCR (diazoxide choline), Carbetocin (LV-101), ARD-101, RGH-706, PBF-999, CSTI-500, and others
• Prader-Willi Syndrome Therapeutic Assessment: Prader-Willi Syndrome current marketed and Prader-Willi Syndrome emerging therapies
• Prader-Willi Syndrome Market Dynamics: Prader-Willi Syndrome market drivers and Prader-Willi Syndrome market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Prader-Willi Syndrome Unmet Needs, KOL's views, Analyst's views, Prader-Willi Syndrome Market Access and Reimbursement

To know more about Prader-Willi Syndrome companies working in the treatment market, visit @ Prader-Willi Syndrome Clinical Trials and Therapeutic Assessment- https://www.delveinsight.com/sample-request/prader-willi-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Prader-Willi Syndrome Market Report Introduction
2. Executive Summary for Prader-Willi Syndrome
3. SWOT analysis of Prader-Willi Syndrome
4. Prader-Willi Syndrome Patient Share (%) Overview at a Glance
5. Prader-Willi Syndrome Market Overview at a Glance
6. Prader-Willi Syndrome Disease Background and Overview
7. Prader-Willi Syndrome Epidemiology and Patient Population
8. Country-Specific Patient Population of Prader-Willi Syndrome
9. Prader-Willi Syndrome Current Treatment and Medical Practices
10. Prader-Willi Syndrome Unmet Needs
11. Prader-Willi Syndrome Emerging Therapies
12. Prader-Willi Syndrome Market Outlook
13. Country-Wise Prader-Willi Syndrome Market Analysis (2020-2034)
14. Prader-Willi Syndrome Market Access and Reimbursement of Therapies
15. Prader-Willi Syndrome Market Drivers
16. Prader-Willi Syndrome Market Barriers
17. Prader-Willi Syndrome Appendix
18. Prader-Willi Syndrome Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.